Late sacral recurrence of rectal cancer treated by heavy ion radiotherapy: a case report by unknown
CASE REPORT Open Access
Late sacral recurrence of rectal cancer
treated by heavy ion radiotherapy: a case
report
Hiroyuki Matsuzaki1* , Soichiro Ishihara1, Kazushige Kawai1, Takeshi Nishikawa1, Toshiaki Tanaka1,
Tomomichi Kiyomatsu1, Keisuke Hata1, Hiroaki Nozawa1, Shigeru Yamada2 and Toshiaki Watanabe1
Abstract
Background: The need for surveillance of rare late recurrence of rectal cancer has not yet been established. Local
control of unresectable skeletal metastasis is important for palliation of symptoms and support for systemic
chemotherapy.
Case presentation: A Japanese man underwent preoperative pelvic irradiation (50.4 Gy/28 Fr) and low anterior
resection at the age of 57 years. The pathological stage was II (T3N0M0). Nine years after the surgery, his
carcinoembryonic antigen (CEA) level showed rapid elevation, although he had no symptoms. A computed
tomography (CT) scan showed no evidence of recurrent lesions, but positron emission tomography (PET)-CT
revealed abnormally high 2-[18F]-fluoro-2-deoxy-D-glucose accumulation in the sacrum. A CT-guided needle biopsy
confirmed the diagnosis of metastatic adenocarcinoma from the previous rectal cancer. The sacral metastasis
reached the S1/S2 level and was considered inoperable. Conventional radiotherapy was also excluded due to the
previous history of pelvic irradiation. Finally, heavy ion radiotherapy with carbon ions was performed as radical local
therapy (70.4 GyE/16 Fr). The patient did not consent to systemic chemotherapy immediately after the irradiation.
Five months after radiotherapy, multiple lung metastases were noted on CT, followed by mediastinal and hilar
lymph node metastases. Systemic chemotherapy was started 9 months after the irradiation. During this time, the
patient experienced some degree of pain and loss in muscle strength of the left lower limb, and a second heavy
ion irradiation (60.0 GyE/12 Fr) was performed 11 months after the previous irradiation. After that, the sacral lesion
has been stable and his symptoms have not worsened. Two years after the heavy ion therapy, the patient steadily
continues outpatient chemotherapy and his quality of life is relatively maintained.
Conclusion: In case the risk of late recurrence is relatively high after rectal cancer surgery, clinicians should
consider individual follow-up evaluations, including CEA measurements to allow for timely diagnosis and
intervention. Heavy ion radiotherapy is effective for local control of sacral metastasis.
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Background
Most recurrences of colorectal cancer occur within
5 years after curative resection, and the guidelines recom-
mend a 5-year postoperative follow-up [1, 2]; however, a
few cases do show relapse beyond this time period, with
symptomatic and sometimes advanced stages causing
severe complications. Bone metastasis from colorectal
cancer is a relatively rare event [3–6], but it is often ac-
companied by serious problems such as pain, paralysis,
and pathological fractures; therefore, therapeutic interven-
tion is required as early as possible. There is no estab-
lished treatment for bone metastases from colorectal
cancer, and palliative radiotherapy is sometimes used for
pain control and prevention of pathological fracture. On
the other hand, heavy ion radiotherapy using carbon ions
has been reported to be effective for local recurrence of
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rectal cancer [7–9]. Here, we report a rare and interesting
case of a late sacral recurrence treated with heavy ion
radiotherapy 9 years after the curative resection of a pri-
mary rectal cancer.
Case presentation
A 57-year-old man was referred to our hospital because
of blood in the stool, and he was diagnosed with clinical
stage II (T3N0M0) rectal cancer in 2004. The preoperative
carcinoembryonic antigen (CEA) level (8.1 ng/ml) was
slightly above the normal range (0–5.0 ng/ml). Preopera-
tive pelvic irradiation with 50.4 Gy/28 Fr was performed,
and the tumor decreased in size. Low anterior resection
was performed.
The resected specimen contained a 2.0-cm × 2.0-cm
moderately differentiated adenocarcinoma with slight
venous invasion and partial effect of irradiation and was
diagnosed as stage II (T3N0M0) according to the Union
for International Cancer Control TNM staging system.
The surgical margin was negative. The blood CEA level
dropped to the normal value soon after the operation.
Adjuvant 5′-deoxy-5-fluorouridine was orally adminis-
tered for 2 years after the operation. The follow-up ex-
aminations showed no sign of recurrence, and 5 years
after the surgery, the follow-up was continued with an-
nual computed tomography (CT) scans and biannual
blood tests, including CEA measurements.
Nine years after the surgery, the CEA level showed a
rapid elevation to 21.7 ng/ml, although the patient had
no symptoms (Fig. 1). A CT scan showed no evidence of
recurrent lesions, but a positron emission tomography
(PET)-CT scan revealed abnormally high 2-[18F]-fluoro-
2-deoxy-D-glucose (FDG) accumulation only in the
sacrum (Fig. 2). A CT-guided percutaneous needle bi-
opsy of the sacral tumor confirmed the diagnosis of
metastatic adenocarcinoma from the previous rectal can-
cer. The sacral metastatic lesion reached the left S1/S2
level, and the possibility of surgery was excluded to
avoid nerve injury. Conventional radiotherapy was also
excluded due to the previous history of irradiation to the
pelvis. The primary rectal lesion had a RAS mutation.
Finally, heavy ion irradiation with carbon ions was per-
formed as radical local therapy (70.4 GyE/16 Fr). The ir-
radiation was performed as one of the “advanced
medical treatments,” stipulated by the Ministry of
Health, Labour and Welfare in Japan, after approval by
the hospital case review committee. Written and in-
formed consent was obtained from the patient. The dose
was calculated for the target volume and any nearby critical
structures and expressed in gray equivalent (GyE = carbon
physical dose (Gy) × relative biologic effectiveness (RBE)).
The CEA level reached a maximum of 55.6 ng/ml im-
mediately after the heavy ion therapy and then gradually
decreased to a minimum of 7.0 ng/ml 3 months after the
irradiation.
Considering the possibility of distant metastasis, the op-
tion of adjuvant systemic chemotherapy was presented
but rejected by the patient. Four months after the heavy
ion therapy, the CEA level was elevated again to
11.0 ng/ml and continued to increase thereafter. Multiple
Fig. 1 Course of treatment and changes in blood CEA level
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small lung metastases were noted on CT scans 5 months
after the radiotherapy (Fig. 3), but the sacral lesion was
stable. At first, resection of the lung metastases was con-
sidered, but this was eventually decided against because
the PET-CT scan showed the appearance of mediastinal
and hilar lymph node metastases 8 months after the radio-
therapy (Fig. 4).
Systemic chemotherapy (mFOLFOX6 + bevacizumab)
was started 9 months after the heavy ion radiotherapy.
After three courses of the regimen, the patient devel-
oped acute hemorrhagic cholecystitis and was treated
conservatively. Around the same time, he developed a
decrease in left lower limb muscle strength and needed
a wheelchair or walking brace when going out. Further-
more, left limb pain increased and pain control was
started with oral administration of tapentadol, pregaba-
lin, and oxycodone. Around the same time, a follow-up
CT scan revealed asymptomatic pulmonary arterial and
left lower limb deep vein thrombosis, and an oral anti-
coagulant was started. These bleeding and thrombosis
events were thought to be side effects of bevacizumab,
which was stopped thereafter.
Eleven months after the irradiation, the sacral lesion
showed slight progression with worsening of pain, and the
second course of heavy ion irradiation (60.0 GyE/12 Fr)
was administered. After the irradiation, the sacral lesion
remained stable (Fig. 5) and there was no further worsen-
ing of pain. Two years after the first heavy ion irradiation,
mFOLFOX6 has been continued for 25 courses and the
regimen is planned to be changed to FOLFIRI because of
the progression of both the lung metastases and the me-
tastases in the mediastinal lymph nodes. There is no sign
of further progression of the sacral lesion. The patient
steadily continues outpatient chemotherapy without fur-
ther worsening of the symptoms. His quality of life is rela-
tively maintained; he travels abroad in a wheelchair once
Fig. 2 FDG-PET showing sacral recurrence 9 years after the surgery on the primary tumor. FDG-PET-CT shows abnormally high accumulation of
FDG in the first and second segments of the sacrum 9 years after resection of the primary rectal cancer
Fig. 3 Chest CT 5 months after heavy ion radiotherapy. The chest CT shows multiple lung metastases 5 months after the heavy ion
radiotherapy (circles)
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every few months with the help of his wife, after the ad-
ministration of pain control drugs.
Discussion
Most recurrences of colorectal cancer occur within 5 years
after curative surgery, and the guidelines in America and
Japan recommend a 5-year postoperative follow-up [1, 2].
However, a few cases do show relapse after an interval of
more than 5 years, and there is no recommendation on
surveillance for such possible late recurrences. Some risk
factors of late recurrence have been reported, including
rectal location of the cancer, early stage at diagnosis, neo-
adjuvant (chemo)radiation therapy for rectal cancer,
pathologically well-differentiated disease, and low venous
invasion [10–13]. Merkel et al. recommended at least
7–8 years of follow-up after long-term neoadjuvant
radiotherapy or chemoradiotherapy for rectal cancer,
because of the high rate of local recurrences noted more
than 5 years after the primary therapy [10]. With respect
to the mechanism involved in the late recurrence in rectal
cancer patients who had received long-term neoadjuvant
(chemo)radiation therapy, our literature search did not re-
veal any convincing results.
In the case we report here, the patient had received
preoperative radiotherapy and therefore had a potential
risk of late recurrence. Under such a condition, a rapid
elevation of the CEA level led to further investigations
to identify metastatic lesions. If the follow-up had been
terminated at the 5-year limit, the sacral metastasis
would not have been diagnosed until the patient devel-
oped symptoms due to the metastatic lesion. Although
CEA measurement is widely performed in the postoper-
ative follow-up of colorectal cancer for the detection of
asymptomatic recurrence, there is no established recom-
mendation about how often or until when CEA levels
should be monitored [14–16]. For relatively young and
healthy patients who can be candidates for radical ther-
apy if metastatic lesions are found, annual or biannual
CEA measurements may be a good choice for the detec-
tion of late recurrence, in case the assumed recurrence
risk is relatively high. Of course, ongoing evaluation is
necessary of the effectiveness of CEA measurement, in-
cluding long-term efficacy and cost.
FDG-PET has been reported to be useful in the diag-
nosis of recurrent cancer, including colorectal cancer
[17–19]. Flanagan et al. reported that, in 22 colorectal
cancer patients with abnormal postoperative CEA levels
but negative results on conventional imaging studies, the
positive predictive value of FDG-PET was 89 % (15 of
17) and the negative predictive value was 100 % (5 of 5)
[20]. In our case, a conventional CT scan could not show
the metastatic lesion, even when examined retrospectively,
while PET-CT could detect abnormally high FDG ac-
cumulation in the sacrum. Therefore, we conclude
that PET-CT should be performed to search for metastatic
or recurrent lesions undetectable by other imaging tests.
As there are no definitive or routine follow-up sched-
ules for late recurrence, we should consider tailoring
them based on each individual case. For relatively young
and healthy patients who may be candidates for radical
therapy for metastatic lesions, annual or biannual CEA
measurements/digital examination/(PET-) CT may be
appropriate choices for the detection of late recurrence.
CEA measurement and digital examination may be ideal
since they are easy to perform with relatively low cost
and low invasiveness. In terms of ceasing follow-up, 7–
10 years may be sufficient, although there is no support-
ing evidence. Merkel et al. recommend at least 7–8 years
of follow-up after long-term neoadjuvant radiotherapy
or chemoradiotherapy [10]. However, in the current
case, the recurrence occurred 9 years after the primary
surgery. It is important to take into consideration the
patients’ age, comorbidity, activities of daily living, and
hope for intensive follow-up. At any rate, we think rou-
tine termination of follow-up at 5 years may not always
be appropriate for those patients with a potentially high
risk of late recurrence.
Fig. 4 FDG-PET 9 months after heavy ion radiotherapy. PET-CT
shows mediastinal and hilar lymph node metastases 9 months after
the heavy ion radiotherapy
Fig. 5 PET-CT 2 months after the second course of heavy ion
radiotherapy. PET-CT shows disappearance of the abnormal
accumulation in the sacral lesion 2 months after the second
course of heavy ion radiotherapy
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Skeletal metastasis is relatively rare in colorectal can-
cer compared with the more common liver, peritoneal,
and lung metastases. In previous case series, the rate of
skeletal metastasis has been reported to be approxi-
mately 6 % [3, 4]. In recent decades, higher rates of bone
metastasis have been documented in association with
the administration of multiple systemic treatments [5, 6].
Sundermeyer et al. reported that 10.4 % of patients with
metastatic colorectal carcinoma developed bone metasta-
ses, and the frequency of this event increased with the
number of chemotherapy drugs used, from 3.7 % in cases
of no systemic chemotherapy to 17.4 % in cases where
four to five agents were used; they added that bone
metastases develop more frequently in rectal cancer
than in colon cancer [5]. Katoh et al. reported that 23.7 %
(28/118) of autopsy cases with colorectal cancer had bone
metastases [21]. In our case, the sacral metastasis would
be from blood circulation including Batson’s venous
plexus [22] because initial pathological findings showed
no lymph node metastasis nor lymphatic invasion.
There is no established treatment for skeletal metasta-
ses from colorectal cancer. Conventional radiotherapy
alone can hardly be considered a radical treatment but is
still effective for the prevention and palliative treatment
of symptoms from bone metastases, such as pain, paraly-
sis, and pathological fracture. Surgical resection is con-
sidered when the metastasis is limited to a single bone
site and is curable, if the associated risk of surgery is ac-
ceptable. For sacral metastasis, surgery is usually not in-
dicated for S1/S2 lesions because of the high risk of
neurological complications. Moriya et al. reported that,
in 57 patients with locally recurrent rectal cancer who
underwent total pelvic exenteration with distal sacrect-
omy, the most frequent complication was sacral wound
dehiscence (51 % of patients), followed by pelvic sepsis
(39 %), but serious complications such as walking im-
pairment and spinal fluid leak did not occur since their
guidelines included preservation of the S2 sacral nerves
bilaterally [23]. Fourney et al. reported that, in 29 pa-
tients who underwent en bloc resection of primary sacral
tumors, the rates of walking impairment when the level
of sacrectomy included S1 and below S1 were 40 and
14 %, respectively, but no patients had walking impair-
ment if the sacrectomy was below S2 [24].
In the current case, a sacrectomy was decided against
because the metastatic lesion reached the S1/S2 level
and the risk of nerve injury was high. Conventional
radiotherapy was also not indicated because of the his-
tory of preoperative pelvic irradiation. On the other
hand, heavy ion radiotherapy using carbon ions has been
reported to produce good clinical results for local recur-
rence of rectal cancer [7–9]. Yamada et al. performed a
phase I/II study in which 180 patients were treated with
carbon ion radiotherapy for locally recurrent rectal
cancer. In their study, no patients experienced acute re-
actions of National Comprehensive Cancer Network
grade 3 to 5 severity; the local control rates in patients
treated with 67.2, 70.4, and 73.6 GyE at 5 years were 35,
77, and 88 %, respectively; the overall survival rates in
patients treated with 73.6 GyE were 78 % at 3 years and
59 % at 5 years [25]. They also reported another study in
which 23 patients were treated with carbon ion radio-
therapy (70.4 GyE) as re-irradiation for locally recurrent
rectal cancer. In this study, grade 3 toxicities occurred in
six (26 %) patients and the 1- and 3-year overall survival
rates were 83 and 72 %, respectively [26]. Habermehl et
al. also reported that, in 19 patients treated with carbon
ion radiotherapy as re-irradiation of local recurrence of
rectal cancer, the estimated mean local progression-free
survival was 20.6 months with no grade 3 or higher tox-
icities [9].
To avoid the complication of bowel perforation from
heavy ion therapy, the recurrent lesion must be sepa-
rated from the intestinal wall by a space of at least
5 mm; our case met this criterion. If the spacing is not
adequate, heavy ion radiotherapy can be performed
safely by surgically inserting a spacer between the target
lesion and the intestinal wall.
In the current case, pain and palsy occurred 1 year
after the first course of heavy ion radiotherapy. At first,
the nerve disorder may have been an adverse event as a
result of the heavy ion radiotherapy. It generally occurs
6–12 months after irradiation, in a small number of
people. Since this patient had undergone conventional
neoadjuvant radiotherapy during the primary treatment,
the accumulative dose to the nerve was high, which may
be one of the causes of the nerve disorder. However, as
for the worsening of pain prior to the second course of
heavy ion radiotherapy, we do not think it was merely
an adverse event; in fact, we think it was a symptom of
sacral lesion progression. In fact, after the second heavy
ion irradiation, further worsening of the nerve disorder
ceased and we thought the irradiation was effective. If
we had not intervened at the time of diagnosis, far more
severe destruction of the sacrum and refractory pain
might have occurred.
We performed a PubMed search of the literature using
the keywords “heavy ion,” “carbon ion,” and “colorectal
cancer” and found no reported case of heavy ion radio-
therapy for bone metastasis from colorectal cancer. In
our case, the heavy ion radiotherapy, which was poten-
tially radical at the time of the irradiation, was unfortu-
nately soon followed by the development of systemic
metastases. Nevertheless, the sacral metastasis has been
stable after the second heavy ion irradiation, and the pa-
tient’s quality of life has been relatively maintained until
now. The patient steadily continues outpatient chemo-
therapy and enjoys his everyday life, including occasional
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foreign trips with his family. Quality of life is very import-
ant in cancer patients, especially those with advanced-stage
disease. Heavy ion irradiation to the sacral lesion was
considered effective for local control, continuation of
systemic therapy, and eventually for maintenance of
the quality of life.
Conclusions
We encountered a rare case of late asymptomatic sacral
recurrence of rectal cancer diagnosed by a rapid CEA
level elevation 9 years after the primary surgery. Heavy
ion irradiation to the sacral lesion was effective for local
control. We conclude that, if the risk of late recurrence
is expected to be relatively high, clinicians should con-
sider individual follow-up evaluations, including CEA
measurement, even beyond the 5-year limit, to allow
timely diagnosis and intervention.
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